Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Cancer Res (2010) 70 (2): 621–631.

https://doi.org/10.1158/0008-5472.CAN-09-2340

Published: 13 January 2010

View article titled, Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Includes: Supplementary data

Journal Articles

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu, Lourdes Toral-Barza, Celine Shi, Wei-Guo Zhang, Judy Lucas, Boris Shor, Jamie Kim, Jeroen Verheijen, Kevin Curran, David J. Malwitz, Derek C. Cole, John Ellingboe, Semiramis Ayral-Kaloustian, Tarek S. Mansour, James J. Gibbons, Robert T. Abraham, Pawel Nowak, Arie Zask

Cancer Res (2009) 69 (15): 6232–6240.

https://doi.org/10.1158/0008-5472.CAN-09-0299

Published: 29 July 2009

View article titled, Biochemical, Cellular, and <em>In vivo</em> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Includes: Supplementary data

Journal Articles

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Cancer Res (2009) 69 (9_Supplement): 3713.

Published: 01 May 2009

View article titled, Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Journal Articles

Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

Arie Zask, Jeroen Verheijen, Joshua Kaplan, Kevin Curran, David Richard, Natasja Brooijmans, Judy Lucas, Lourdes Toral-Barza, Wei-Guo Zhang, Irwin Hollander, James Gibbons, Robert Abraham, Semiramis Ayral-Kaloustian, Tarek Mansour, Ker Yu

Cancer Res (2009) 69 (9_Supplement): 2014.

Published: 01 May 2009

View article titled, Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

Journal Articles

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Boris Shor, Wei-Guo Zhang, Lourdes Toral-Barza, Jessica Lucas, Robert T. Abraham, James J. Gibbons, Ker Yu

Cancer Res (2008) 68 (8): 2934–2943.

https://doi.org/10.1158/0008-5472.CAN-07-6487

Published: 15 April 2008

View article titled, A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Includes: Supplementary data

NARROW

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Email alerts

AACR Journals

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Abstract #2014: ATP competitive inhibitors of the mammalian target of rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with potent in vivo antitumor activity

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only